Cargando…

Triple Negative Breast Cancers Have a Reduced Expression of DNA Repair Genes

DNA repair is a key determinant in the cellular response to therapy and tumor repair status could play an important role in tailoring patient therapy. Our goal was to evaluate the mRNA of 13 genes involved in different DNA repair pathways (base excision, nucleotide excision, homologous recombination...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ribeiro, Enilze, Ganzinelli, Monica, Andreis, Daniele, Bertoni, Ramona, Giardini, Roberto, Fox, Stephen B., Broggini, Massimo, Bottini, Alberto, Zanoni, Vanessa, Bazzola, Letizia, Foroni, Chiara, Generali, Daniele, Damia, Giovanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3692506/ https://www.ncbi.nlm.nih.gov/pubmed/23825533 http://dx.doi.org/10.1371/journal.pone.0066243

Ejemplares similares

Expression of genes involved in DNA repair and cell cycle checkpoint pathways in Triple Negative compared to Luminal A Breast Cancer: a molecular characterization
por: Ganzinelli, Monica, et al.
Publicado: (2012)

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer
por: Allevi, G, et al.
Publicado: (2013)

Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer
por: Bazzola, L, et al.
Publicado: (2015)

Characterization of MTAP Gene Expression in Breast Cancer Patients and Cell Lines
por: de Oliveira, Sarah Franco Vieira, et al.
Publicado: (2016)

Platinum Resistance in Ovarian Cancer: Role of DNA Repair
por: Damia, Giovanna, et al.
Publicado: (2019)

Epithelioid Mesothelioma Patients with Very Long Survival Display Defects in DNA Repair
por: Ganzinelli, Monica, et al.
Publicado: (2023)

The 5′UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs
por: Rulli, Eliana, et al.
Publicado: (2016)

Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts
por: Guffanti, Federica, et al.
Publicado: (2018)

Evaluation of safety and efficacy of tivantinib in the treatment of inoperable or recurrent non-small-cell lung cancer
por: Broggini, Massimo, et al.
Publicado: (2013)

Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts
por: Ricci, Francesca, et al.
Publicado: (2017)

Down-regulation of the Nucleotide Excision Repair gene XPG as a new mechanism of drug resistance in human and murine cancer cells
por: Sabatino, Maria Antonietta, et al.
Publicado: (2010)

Would the combination of everolimus with endocrine-therapy help in FGFR2 positive serous endometrial cancer?
por: Cappelletti, Maria Rosa, et al.
Publicado: (2015)

Lack of Efficacy: When Opioids Do Not Achieve Analgesia from the Beginning of Treatment in Cancer Patients
por: Corli, Oscar, et al.
Publicado: (2019)

Multi-Chemotherapeutic Schedules Containing the pan-FGFR Inhibitor ARQ 087 are Safe and Show Antitumor Activity in Different Xenograft Models()
por: Chilà, Rosaria, et al.
Publicado: (2017)

Present and Future Perspective on PLK1 Inhibition in Cancer Treatment
por: Chiappa, Michela, et al.
Publicado: (2022)

Predictive modeling of gene expression regulation
por: Regondi, Chiara, et al.
Publicado: (2021)

Next-Generation Sequencing and Triple-Negative Breast Cancer: Insights and Applications
por: Tierno, Domenico, et al.
Publicado: (2023)

Breast tumour angiogenesis
por: Fox, Stephen B, et al.
Publicado: (2007)

COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment
por: Generali, D, et al.
Publicado: (2014)

Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: A meta-analysis of randomized trials
por: Roviello, Giandomenico, et al.
Publicado: (2016)

Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2− advanced breast cancer
por: Corona, Silvia Paola, et al.
Publicado: (2018)

Evolution of gossip-based indirect reciprocity on a bipartite network
por: Giardini, Francesca, et al.
Publicado: (2016)

Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells
por: Ozawa, Patricia Midori Murobushi, et al.
Publicado: (2018)

The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen
por: Fox, Stephen B, et al.
Publicado: (2011)

DNA repair deficiency as circulating biomarker in prostate cancer
por: Catalano, Martina, et al.
Publicado: (2023)

Impact of ERCC1, XPF and DNA Polymerase β Expression on Platinum Response in Patient-Derived Ovarian Cancer Xenografts
por: Guffanti, Federica, et al.
Publicado: (2020)

PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy
por: Sobhani, Navid, et al.
Publicado: (2017)

The combination of bevacizumab with chemotherapy is more beneficial in the metastatic setting rather than in the adjuvant setting for the treatment of HER2-negative breast cancer—a commentary on the E5103 randomized phase III clinical study
por: Roviello, Giandomenico, et al.
Publicado: (2019)

Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer
por: Nafi, Siti Norasikin Mohd, et al.
Publicado: (2014)

PD-1/PD-L1 Inhibitors Response in Triple-Negative Breast Cancer: Can Long Noncoding RNAs Be Associated?
por: Mathias, Carolina, et al.
Publicado: (2023)

MiR-150-5p Overexpression in Triple-Negative Breast Cancer Contributes to the In Vitro Aggressiveness of This Breast Cancer Subtype
por: Sugita, Bruna M., et al.
Publicado: (2022)

Role of the IGF-1 Axis in Overcoming Resistance in Breast Cancer
por: Ianza, Anna, et al.
Publicado: (2021)

Patients’ Engagement in Early Detection of COVID-19 Symptoms: An Observational Study in the Very Early Peak of the Pandemic in Italy in 2020
por: Palamenghi, Lorenzo, et al.
Publicado: (2022)

Association of FOSL1 copy number alteration and triple negative breast tumors
por: Serino, Leandro Tamião Rodrigues, et al.
Publicado: (2019)

Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736
por: Restelli, Valentina, et al.
Publicado: (2015)

Triple-helical nanowires by tomographic rotatory growth for chiral photonics
por: Esposito, Marco, et al.
Publicado: (2015)

Clinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidence
por: Rocca, Andrea, et al.
Publicado: (2018)

Rising cross sections and the triple pomeron
por: Amati, Daniele, et al.
Publicado: (1973)

Glyphosate ingestion causing multiple organ failure: a near-fatal case report
por: Picetti, Edoardo, et al.
Publicado: (2017)

Cyclin dependent kinase 4 and 6 inhibitors as novel therapeutic agents for targeted treatment of malignant mesothelioma
por: Sobhani, Navid, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_899t4im8o0gk4ph1id90hm4m0o